Silver polyvinyl pyrrolidone nanoparticles exhibit a capsular polysaccharide influenced bactericidal effect against Streptococcus pneumoniae

Ronda K. Bibbs1, Rhonda D. Harris1, Veolanda A. Peoples1, Cleon Barnett2, Shree R. Singh1, Vida A. Dennis1 and Mamie T. Coats1,3 *

1 Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL, USA
2 Department of Physical Sciences, Alabama State University, Montgomery, AL, USA
3 Department of Biological Sciences, Alabama State University, Montgomery, AL, USA

Streptococcus pneumoniae remains a leading cause of morbidity and mortality worldwide. The highly adaptive nature of S. pneumoniae exemplifies the need for next generation antimicrobials designed to avoid high level resistance. Metal based nanomaterials fit this criterion. Our study examined the antimicrobial activity of gold nanospheres, silver coated polyvinyl pyrrolidone (AgPVP), and titanium dioxide (TiO2) against various serotypes of S. pneumoniae. Twenty nanometer spherical AgPVP demonstrated the highest level of killing among the tested materials. AgPVP (0.6 mg/mL) was able to kill pneumococcal serotypes 2, 3, 4, and 19F within 4 h of exposure. Detailed analysis of cultures during exposure to AgPVP showed that both the metal ions and the solid nanoparticles participate in the killing of the pneumococcus. The bactericidal effect of AgPVP was lessened in the absence of the pneumococcal capsular polysaccharide. Capsule negative strains, JD908 and RX1, were only susceptible to AgPVP at concentrations at least 33% higher than their respective capsule expressing counterparts. These findings suggest that mechanisms of killing used by nanomaterials are not serotype dependent and that the capsular polysaccharide participates in the inhibition. In the near future these mechanisms will be examined as targets for novel antimicrobials.

Keywords: AgPVP, pneumococcus, nanoparticle, serotype, antimicrobial, titanium dioxide

INTRODUCTION

Streptococcus pneumoniae (pneumococcus) is an encapsulated, Gram-positive, facultative anaerobic bacterium which is a common commensal in the nasopharynx of healthy adults and children (Zemlickova et al., 2006; Calix et al., 2012; Marks et al., 2013). Asymptomatic carriage of S. pneumoniae can lead to invasive and non-invasive infections (Morona et al., 2004; Abdelnour et al., 2009; Ghasemi et al., 2009). Symptomatic disease will occur when the bacterium migrates to normally sterile organs such as the lungs, spinal cord, and middle ear (Murkerji et al., 2012). Such infections have been associated with high morbidity and mortality in young children under 5 years of age, the elderly, and immunocompromised especially in developing countries (Ghasemi et al., 2009; Mehr and Wood, 2012). Annually, in the United States, there are an estimated 500,000 cases of pneumonia, 50,000 cases of bacteremia, 3,000–6,000 cases of meningitis, 7,000,000 cases of otitis media with the major cause being pneumococcus (Temime et al., 2008; Daka et al., 2011; CDC, 2013). It has also been estimated by the World Health Organization that 2 million children, under the age of five, die each year from complications associated with pneumococcal pneumonia including endobronchial obstruction, empyema, and pericarditis (Bryce et al., 2005).

The highly recombinant nature of S. pneumoniae in combination with naturally occurring antibiotic resistance and the overuse of antibiotics are all likely to contribute to the organism’s increasing levels of antibiotic insensitivity. While β-lactams remain the preferred treatment for pneumococcal infection, their usefulness is limited due to increasing resistance to several classes of antimicrobials. The morbidity and mortality associated with pneumococcal infections, as well as the ever declining level of antibiotic susceptibility and limited usefulness of prophylaxis, point to the need for novel antimicrobials.

Nanomaterials have shown some usefulness in killing pathogenic bacteria. Some nanoparticles (NPs), typically on the 0.2–100 nm scale, (El-Nour et al., 2010; Beer et al., 2012; Sun et al., 2013) are finding increasing application as antimicrobials and additives in food packaging, industrial and consumer products (Ravishankar and Jamuna, 2011; Sahayaraj and Rajesh, 2011; Ivask et al., 2012). Metal NPs have been of great interest due to their physiochemical properties (e.g., electromagnetic, optic and molecular recognition, and catalytic) that differ from bulk materials of micro-size (Kaittanis et al., 2010; Sadeghi et al., 2010; Ahmad et al., 2013). Higher activity of nanoscale materials is a result of their surface-to-volume ratios. As the material becomes smaller, the percentage of active molecules/atoms present at the surface increases compared to larger bulk material.

The advantages of using metallic NPs are as follows: (1) core of the material is inert, (2) exploitation of both chemical and physical properties enables them to carry and release various therapeutic
agents, (3) synthesis is relatively simple and (4) mechanism of action allows versatility. Once the metal is ionized, it becomes very reactive as it interacts with thiol group of respiratory enzymes that are located in the bacterial cell wall or cell membrane (Ghosh et al., 2008). When the NPs enter the cell, they will migrate to the center of the bacteria. The bacteria congregate in an effort to protect its DNA from the metal ions. This event will eventually cause the DNA to condense leading to the retardation of the respiratory chain, cell division, and finally cell death (Rai et al., 2009; Sadeghi et al., 2010; Arshi et al., 2011). Microbes would need to acquire a range of mutations to gain resistance against the metals effects. This makes NPs good candidates as antimicrobial agents.

The goals of the current study were to examine the antimicrobial effect of metallic NPs against clinically relevant serotypes of S. pneumoniae and to determine if the capsular polysaccharide plays a role in the inhibition. Each of these findings is novel to S. pneumoniae research.

MATERIALS AND METHODS
NANOPARTICLE AND SYNTHESIS
Silver polyvinyl pyrrolidone (AgPVP) coated NPs (20 nm) and titanium dioxide (Anatase; 15 nm) were purchased from Nanostructured and Amorphous Materials, Inc. (Houston, TX, USA). Gold nanospheres were synthesized from hydrogen tetrachloroaurate (III), HAuCl₄, (Sigma Aldrich; Kimling et al., 2006). Gold hydrochlorate (HAuCl₄) was dissolved in deionized water and heated to 100°C. Gold was monitored using Au I at 267.60 nm and while titanium dioxide (95 mg/mL), AgPVP (0.6 mg/mL), and activity of gold nanospheres (AuNP; 1 mg/mL) were incubated individually in THY media for 5 h at 37°C. Ag and Au ions released into the media were measured using laser induced breakdown spectroscopy (LIBS). The measurement settings were a modification of Barnett et al. (2011). The excitation wavelength used was 266 nm and the laser energy was adjusted to 20 mJ. The spectrometer and detector were changed to the Andor Shamrock 303i – iStar – DH320T-25F-03 with gating at 2400 l/mm. Data was collected approximately 1.5 µs after the plasma started and the signal was integrated for 3.0 µs. Gold was monitored using Au I at 267.60 nm and while silver was monitored using Ag I at 328.07 and 338.29 nm.

CHARACTERIZATION OF S. pneumoniae/AgPVP INTERACTIONS
Streptococcus pneumoniae D39 (1.0 × 10⁸ CFU/mL) was grown in THY in the presence of AgPVP (0.6 mg/mL) NPs and incubated at 37°C for 5 h. At various time points, cultures were pelleted by centrifugation for 15 min at 2012 × g. After centrifugation, the supernatant was removed and the pellet was washed using phosphate buffer saline (1XPBS) then pelleted. Bacteria were fixed using 2.5% Glutaraldehyde, 1% osmium tetroxide, and 1XPBS. Images were captured via Scanning electron microscopy (ZEISS EVO 50VP).

Table 1 | Streptococcus pneumoniae strains included in the study.

| Name | Serotype | Background strain | Penicillin | Erythromycin | Reference |
|------|----------|-------------------|------------|-------------|-----------|
| D39  | 3        | NA                | Sensitive  | Sensitive   | Magee and Yother (2001), Sanders et al. (2011), Murkerji et al. (2012) |
| WU2  | 3        | NA                | Sensitive  | Sensitive   | Magee and Yother (2001), Li et al. (2009), Ren et al. (2012) |
| TIGR4| 4        | NA                | Sensitive  | Sensitive   | Weinberger et al. (2009), Melin et al. (2010), Murkerji et al. (2012) |
| EF3030| 19F      | NA                | Sensitive  | Sensitive   | Johnston et al. (2006), Coats et al. (2011) |
| RX1  | 2        | D39               | Sensitive  | Sensitive   | Morona et al. (2004), Marks et al. (2012), Murkerji et al. (2012) |
| JD908| 3        | WU2               | R (0.03 µg/mL) | Sensitive | Magee and Yother (2001), Marks et al. (2012) |
STATISTICS
Differences between S. pneumoniae (WT) strains were compared with their capsular negative mutants using a two sample, independent Student t-test. A P value of <0.05 was considered significant.

RESULTS
ANALYSIS OF NANOMATERIALS
Transmission electron microscopy showed the AuNP, AgPVP, and TiO2 to be 20 nm, 20 nm, and 15 nm respectively, with uniform particle distribution (Figure 1A). All particles were spherical. The FT-IR spectra for each NP correlate with the fingerprint expected for the respective particle (Figure 1B) (Huang et al., 2010; Tiwari et al., 2011; Devika et al., 2012).

MINIMUM BACTERICIDAL CONCENTRATIONS
Streptococcus pneumoniae strain D39 was grown in liquid media in the presence of varying concentrations of AuNP, AgPVP, or TiO2. The minimum concentrations of TiO2 and AgPVP needed to kill S. pneumoniae D39 were determined to be 95 mg/mL and 0.6 mg/mL respectively, (Figure 2). AuNP at concentrations up to 0.8 mg/mL were able to cause a maximum decrease of 9% in the culture's viability. Higher concentrations of AuNP were not examined because the bactericidal effect plateaued at concentrations above 0.4 mg/mL (Figure 2). When AgPVP and TiO2 were examined for their ability to kill various S. pneumoniae strains of varying serotypes, AgPVP gave more consistent effects than TiO2 (data not shown). All tests were done in duplicate and repeated twice. The bactericidal action of metallic NPs is largely attributed to the release of metal ions from the particle. The levels of Ag, Au, and Ti in the culture media at the end of the 5 h incubation period were determined to be <2.5 μg/mL, 0.0078 μg/mL and 20 mg/mL respectively.

NON-SEROTYPE DEPENDENT ANTIBACTERIAL ACTIVITY OF AgPVP
The 93 serotypes of S. pneumoniae are not equal in their ability to cause disease or their behavior in vitro. In order to determine the effect of serotype on the antimicrobial effect of metallic nanomaterials, four pathogenic S. pneumoniae serotypes were tested for the ability to survive in the previously determined MBC of AgPVP. S. pneumoniae isolates D39 (serotype 2), WU2 (serotype 3), TIGR4 (serotype 4), and EF3030 (serotype 19F) were grown in the presence of AgPVP (0.6 mg/mL; Figure 3). While all the tested isolates were susceptible to AgPVP at the test concentration, the time required to completely kill the cultures varied. Also, while the time to death varied between the individual strains none survived more than 4 h. Due to the variation in survival times for the individual strains representing the various serotypes, additional strains within the serogroups were tested for survival in the presence of 0.6 mg/mL AgPVP. The length of time individual strains survived varied among strains of the same serotype (data not shown). These findings together suggest that inhibition is not dependent on the serotype.

CAPSULAR POLYSACCHARIDE INFLUENCED KILLING OF S. pneumoniae
The variability in time to death during exposure to AgPVP for the individual serotypes suggests that the capsular polysaccharide may play a role in the interaction between bacteria and NPs.
In order to examine the effect of the pneumococcal capsule on the antimicrobial activity of metallic NPs, *S. pneumoniae* D39, WU2 and their capsular polysaccharide negative mutants, Rx1 and JD908, respectively, were grown for 5 h in the presence of AgPVP (Figure 4). Rx1 and JD908 were found to survive significantly longer and in higher numbers than their respective wild-type counterparts (*P* = 0.0005 and *P* = 0.003, respectively). In fact, the mutant strains lacking capsular polysaccharide remained viable in the presence of AgPVP. RX1 maintained the number of viable colonies while JD908 increased in CFU. Increasing the incubation time did not result in death of the mutant strains due to AgPVP (data not shown). AgPVP concentrations of 0.8 mg/mL and higher were able to kill Rx1 and JD908 *S. pneumoniae*. The growth patterns and responses to AgPVP suggest that the capsular polysaccharide participates in the mechanism used by AgPVP to kill *S. pneumoniae*.

**ULTRASTRUCTURAL EFFECT OF AgPVP**

Scanning electron microscopy of *S. pneumoniae* D39 grown in the presence of AgPVP demonstrated the killing of the bacterial cells in the presence of the nanomaterial (Figures 5D–F). AgPVP alone is shown in Figure 5B. Images were taken at 0 h (Figure 5A) and 5 h incubation (Figures 5C–F). The cell debris remaining following exposure of the bacteria to AgPVP is shown in Figure 5D. Figure 5C shows bacteria grown in the absence of AgPVP. The absence of cell debris in the Figure 5C sample indicates that the debris seen in Figure 5D is not attributable to autolysis of the bacteria. The damage and breakdown of the bacterial capsular polysaccharide and cell wall can be seen in Figure 5E and is indicated by the arrow. Also, while much of the damage done by metallic NPs is thought to be due to the metal ions, the NPs themselves do participate in the inhibition of the bacteria as is seen in Figure 5F which shows AgPVP inside the bacteria (indicated by arrow). As the particles accumulate in the bacteria the bacteria increase in size and eventually lyse.

**DISCUSSION**

For decades, metal ions and metal-based compounds have been used in various capacities due to their antimicrobial properties against different pathogenic microorganisms (Zhou et al., 2012; Ahmad et al., 2013; Lima et al., 2013). The present study is the first detailed examination of the potential use of metallic NPs against clinically relevant serotypes of the formidable human pathogen, *S. pneumoniae*. Due to their varying modes of action, Au, Ag, and TiO2 NPs were examined for antimicrobial effects against *S. pneumoniae*. AgNP showed the most reproducible inhibition. This is likely due to multifaceted damage caused AgNPs including condensation of DNA, cell membrane separation from the cell wall, and cell wall damage (Morones et al., 2005; Seil and Webster, 2012; You et al., 2012). The levels of AgNPs needed to inhibit pneumococcal growth are higher than those reported for other microorganisms (Pelgrift and Friedman, 2013; Losasso et al., 2014). This is likely due to the unique physical characteristics of the bacterium. The lack of inhibition by AuNPs is likely because their antimicrobial effect is due to the targeting of sulfur-containing proteins present in the membrane or inside the cells but *S. pneumoniae* does not contain many such proteins. Also, a much smaller percentage of Au ions were released into the media. TiO2 is more limited in its activity due to the need for activation by UV light or the availability of doped catalysts (Kuhn et al., 2003; Pelgrift and Friedman, 2013).

The role of the capsular polysaccharide in protecting the pneumococcus is well documented (Magee and Yother, 2001; Melin et al., 2010; Sanders et al., 2011). The capsular is also a major contributor for the organism's pathogenicity and is the basis for the 93 known antigenically distinct serotype classifications (Hyams et al., 2010; Hathaway et al., 2012; Wyres et al., 2012). Disease serotypes 2, 3, 4, and 19F were all found to be susceptible to the antimicrobial effects of AgPVP. These serotypes are particularly relevant because isolates of each serotype have been shown to be virulent in animal models of infection as well as human disease (Coats et al., 2011; Hotomi et al., 2013; Okade et al., 2014). This finding supports the likelihood that other disease causing serotypes will be susceptible as well. Having broad range applicability to pneumococcal infection makes NPs far more attractive in the war against pneumococcal infection.

During infection, the capsule protects *S. pneumoniae* from opsonophagocytosis. This protective role of the capsule can appear...
counterintuitive when considered alongside our data showing that \textit{S. pneumoniae} strains completely lacking a capsular polysaccharide were less susceptible to the effects of metallic nanomaterials. In reality, this finding suggests a yet undefined role of the capsule in the presence of metallic ions and possible nanomaterials in general. One possible mechanism is the capsule aiding in the accumulation of metal ions near the cell wall where they can more easily access the cell membrane. A second possibility involves the capsule participating in the movement of metal ions or whole NPs into the bacterial cells.

Additionally, while the capsule polysaccharide appears to participate in killing of the pneumococcus by nanomaterials this does not undermine the use of these nanomaterials in the possible treatment of pneumococcal disease. This is because the capsule polysaccharide is essential for infection by the pneumococcus (Hammerschmidt et al., 2005; Weinberger et al., 2009; Hyams et al., 2010). Thus if the bacteria respond to the presence of an antimicrobial by decreasing its´ capsular polysaccharide, the bacteria would be rapidly cleared by the immune system.

Following exposure to AgPVP, there was a decrease in the viable number of \textit{S. pneumoniae}. This strongly suggests that the bacteria were killed by the NP. Cell death is further supported by the cell lysis that was visible when the culture was examined using microscopy. The breakdown of the cell capsular polysaccharide and cell wall are irreversible and conclusively shows that the organism was not in a viable but non-cultureable state.

The behavior of organisms \textit{S. pneumoniae} in the presence of various nanomaterials provides valuable insight into the possibility of novel antimicrobials to treat pneumococcal diseases. While AgPVP is not likely to be used to treat \textit{S. pneumoniae} infection due to its documented toxicity of Ag and AgNPs (Ahamed et al., 2010; Asharani et al., 2011; Hamilton et al., 2014) the identified vulnerability of different pathways used by AgPVP to inhibit
Bibbs et al. Capsule involved in killing pneumococcus

**FIGURE 5** | Silver coated polyvinyl pyrrolidone has a lytic effect on *S. pneumoniae*. Scanning electron microscopy images of *S. pneumoniae* grown in the presence and absence of AgPVP. *S. pneumoniae* D39 was exposed to AgPVP for 0 (A) and 5 h (C–F). Cultures exposed to AgPVP were compared to unexposed samples (C). AgPVP particles alone imaged as well (B). Samples were deposited onto a glass slide mounted on a stud for imaging.

growth can give new areas on which to focus design of new drugs.

**CONCLUSION**
The results obtained show spherical AgPVP to be preferential to AuNP and TiO₂ for the killing of *S. pneumoniae*. The inhibition occurred within 4 h of exposure to the nanomaterial, was bactericidal in nature and involves the presence of the capsular polysaccharide.

The susceptibility of several disease relevant pneumococcal serotypes to inhibition by AgPVP is particularly encouraging due to the variability of microorganism. The precise role of the capsular polysaccharide in the killing of *S. pneumoniae* needs to be examined. This will require the examination of organisms expressing various levels of the capsule as well as organisms whose serotype has not been identified.

**ACKNOWLEDGMENTS**
This research was supported by funding from the National Science Foundation grants NSF-CREST (HRD-1241701) and NSF-HBCU-UP (HRD-1135863). We thank Drs Janet Yother and David E. Briles, University of Alabama at Birmingham, for isolates and to Dr Michael Miller, Auburn University, for assistance with TEM and SEM images. We would like to give special thanks to the CNBR staff, Yvonne Williams, Lashaundria Lucas, Maiya Moore and Juwanna Smith Henderson, for their time and support.

**REFERENCES**
Abdelnour, A., Soley, C., Guevara, S., Porat, N., Dagan, R., and Arguedas, A. (2009). *Streptococcus pneumoniae* serotype 3 among Costa Rican children with otitis media: clinical, epidemiological characteristics and antimicrobial resistance patterns. *BMC Pediatr.* 9:52. doi: 10.1186/1471-2431-9-52
December 2014 | Volume 5 | Article 665 | 7
www.frontiersin.org

Ahmed, M., Alsalhi, M. S., and Siddiqui, M. K. (2010). Silver nanoparticle applications and human health. *Clin. Chim. Acta* 411, 1841–1848. doi: 10.1016/j.cca.2010.08.016

Ahmad, T., Wani, I. A., Manzoor, N., Ahmed, J., and Asiri, A. M. (2013). Biosynthetic, structural characterization and antimicrobial activity of gold and silver nanoparticles. *Colloids Surf. B* **107**, 227–234. doi: 10.1016/j.colsurfb.2013.02.004

Arshi, N., Ahmed, F., Kumar, S., Anwar, M. S., Koo, B. H., and Lee, C. G. (2011). Comparative study of the Ag/PVP nanocomposites synthesized in water and in ethylene glycol. *Curr. Appl. Phys.* **11**(Suppl. 1), S346–S349. doi: 10.1016/j.cap.2010.11.045

Asharani, P. V., Lianwu, Y., Gong, Z., and Valiyaveettil, S. (2011). Comparison of the toxicity of silver, gold and platinum nanoparticles in developing zebrafish embryos. *Nanotechnology* **5**, 43–54. doi: 10.3109/17435390.2010.489207

Barnett, C., Bell, C., Vig, K., Akpovo, A. C., Johnson, L., Pillai, S., et al. (2012). Capsule type of *Streptococcus pneumoniae* isolated from upper respiratory tract infections in Japan. *PLoS ONE* **7**e58124. doi: 10.1371/journal.pone.0058124

Bibbs et al. Capsule involved in killing *Streptococcus pneumoniae*

Huang, C. N., Bow, I. S., Zheng, Y., Chen, S. Y., Ho, N., and Shen, P. (2010). Nonstoichiometric titanium oxides via pulsed laser ablation in water. *Nanoscale* **2**, 972–985. doi: 10.1039/b011671o-100951-4

Hyams, C., Cambelein, E., Cohen, J. M., Bax, K., and Brown, J. S. (2010). The *Streptococcus pneumoniae* capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. *Infect. Immun.* **78**, 704–715. doi: 10.1128/IAI.00881-09

Ivask, A., George, S., Bondarenko, O., and Kahrul, A. (2012). “Metal-containing nano-antimicrobials: differentiating the impact of solubilized metals and particles,” in *Nano-Antimicrobials: Progress and Prospects*, eds N. Cioffi and M. Rai (Berlin: Springer), 253–290.

Johnston, J. W., Briles, D. E., Myers, L. E., and Hollingshead, S. K. (2006). Mn2+-dependent regulation of multiple genes in *Streptococcus pneumoniae* through PsrK and the resultant impact on virulence. *Infect. Immun.* **74**, 1171–1180. doi: 10.1128/IAI.74.3.1171-1180.2006

Kaitanis, C., Santra, S., and Perez, J. M. (2010). Emerging nanotechnology-based strategies for the identification of microbial pathogenesis. *Adv. Drug Deliv. Rev.* **62**, 408–423. doi: 10.1016/j.addr.2009.11.013

Kimling, M., Maier, M., Okene, B., Kotaisid, V., Ballot, H., and Plech, A. (2006). Turkevich method for gold nanoparticle synthesis revisited. *J. Phys. Chem. B* **110**, 15700–15707. doi: 10.1021/jp061667w

Kuhn, K. P., Chaberny, I. F., Masholder, K., Stickler, M., Benz, V. W., Sonntag, H. G., et al. (2003). Disinfection of surfaces by photocatalytic oxidation with titanium dioxide and UVA light. *Chemosphere* **55**, 71–77. doi: 10.1016/S0045-6535(03)00362-X

Li, J., Zalal, A. J., Hollingshead, S. K., Nahm, M. H., and Briles, D. E. (2009). Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages. *Infect. Immun.* **77**, 464–471. doi: 10.1128/IAI.00892-08

Lima, E., Guerra, R., Lara, V., and Guzmán, A. (2013). Gold nanoparticles as efficient antimicrobial agents for *Escherichia coli* and *Salmonella typhi*. *Chem. Cent. J.* **7**, 11. doi: 10.1186/1752-153X-7-7-11

Losasso, C., Belluco, S., Cibin, V., Zavagnin, P., Misicic, I., Gallocchio, F., et al. (2014). Antibacterial activity of silver nanoparticles: sensitivity of different *Salmonella* serovars. *Front. Microbiol.* **5**, 227. doi: 10.3389/fmicb.2014.00227

Magee, A. D., and Yother, J. (2001). Requirement for capsule in colonization by *Streptococcus pneumoniae*. *Infect. Immun.* **69**, 3753–3761. doi: 10.1128/IAI.69.6.3753-3761.2001

Marks, L. R., Davidson, B. A., Knight, P. R., and Hakansson, A. P. (2013). Interkingdom signaling induces *Streptococcus pneumoniae* biofilm dispersion and transition from asymptomatic colonization to disease. MBio **4**, e00438-13. doi: 10.1128/mBio.00438-13

Marks, L. R., Reddinger, R. M., and Hakansson, A. P. (2012). High levels of genetic recombination during nasopharyngeal carriage and biofilm formation in *Streptococcus pneumoniae*. *MBio* **3**, e00200-12. doi: 10.1128/mBio.00200-12

Mehr, S., and Wood, N. (2012). *Streptococcus pneumoniae*–a review of carriage, infection, serotype replacement and vaccination. *Paediatr. Respir. Rev.* **13**, 258–264. doi: 10.1016/j.prrv.2011.12.001

Meln, M., Trzcinski, K., Meri, S., Käyhty, H., and Väkeväinen, M. (2010). The capsular serotype of *Streptococcus pneumoniae* is more important than the genetic background for resistance to complement. *Infect. Immun.* **78**, 5262–5270. doi: 10.1128/IAI.00740-10

Morona, J. K., Miller, D. C., Morona, R., and Paton, J. C. (2004). The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of *Streptococcus pneumoniae*. *J. Infect.* **189**, 1905–1913. doi: 10.1088/0145-6052/189/10/059

Murkerji, R., Mirza, S., Roche, A. M., Widener, R. W., Coney, C. M., Rhe, D. K., et al. (2012). Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. *J. Immunol.* **189**, 5327–5335. doi: 10.4049/jimmunol.1201967

Okaide, H., Funatsu, T., Eto, M., Furuya, Y., Mizunaga, S., Nomura, N., et al. (2014). Impact of the pneumococcal conjugate vaccine on serotype distribution and susceptibility trends of pediatric non-invasive *Streptococcus pneumoniae* isolates.
Capsule involved in killing pneumococcus

Bibbs et al.

The progress of silver nanoparticles in the antibacterial mechanism, clinical application and cytotoxicity. Mol. Biol. Rep. 39, 9193–9201. doi: 10.1007/s11303-012-1792-8

Zemlickova, H., Urbaskova, P., Adámková, V., Motlová, J., Lebedová, V., and Procházka, B. (2006). Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus isolated from the nasopharynx of healthy children attending day-care centres in the Czech Republic. Epidemiol. Infect. 134, 1179–1187. doi: 10.1017/S0950268806006157

Zhou, Y., Kong, Y., Kundu, S., Cirillo, J. D., and Liang, H. (2012). Antibacterial activities of gold and silver nanoparticles against Escherichia coli and bacillus Calmette-Guerin. J. Nanobiotechnol. 10, 19. doi: 10.1186/1477-3155-10-19

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 15 July 2014; accepted: 16 November 2014; published online: 03 December 2014.

Citation: Bibbs RK, Harris RD, Peoples VA, Barnett C, Singh SR, Dennis VA and Coats MT (2014) Silver polyvinyl pyrrolidone nanoparticles exhibit a capsular polysaccharide influenced bactericidal effect against Streptococcus pneumoniae. Front. Microbiol. 5:665. doi: 10.3389/fmicb.2014.00665

This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology. Copyright © 2014 Bibbs, Harris, Peoples, Barnett, Singh, Dennis and Coats. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.